IL288782B1 - Sustained-release alpha-ketoglutarate preparations - Google Patents

Sustained-release alpha-ketoglutarate preparations

Info

Publication number
IL288782B1
IL288782B1 IL288782A IL28878221A IL288782B1 IL 288782 B1 IL288782 B1 IL 288782B1 IL 288782 A IL288782 A IL 288782A IL 28878221 A IL28878221 A IL 28878221A IL 288782 B1 IL288782 B1 IL 288782B1
Authority
IL
Israel
Prior art keywords
ketoglutarate
sustained
alpha
release compositions
compositions
Prior art date
Application number
IL288782A
Other languages
English (en)
Hebrew (he)
Other versions
IL288782A (en
Original Assignee
Ponce De Leon Health Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Company filed Critical Ponce De Leon Health Designated Activity Company
Publication of IL288782A publication Critical patent/IL288782A/en
Publication of IL288782B1 publication Critical patent/IL288782B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL288782A 2019-06-10 2020-06-10 Sustained-release alpha-ketoglutarate preparations IL288782B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US201962929024P 2019-10-31 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Publications (2)

Publication Number Publication Date
IL288782A IL288782A (en) 2022-02-01
IL288782B1 true IL288782B1 (en) 2026-04-01

Family

ID=73781275

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288782A IL288782B1 (en) 2019-06-10 2020-06-10 Sustained-release alpha-ketoglutarate preparations

Country Status (12)

Country Link
US (1) US20220265586A1 (https=)
EP (1) EP3980001B1 (https=)
JP (2) JP7751291B2 (https=)
KR (1) KR20220044478A (https=)
CN (1) CN114126601B (https=)
AU (1) AU2020292278B2 (https=)
BR (1) BR112021024952A2 (https=)
DK (1) DK3980001T3 (https=)
ES (1) ES3054304T3 (https=)
IL (1) IL288782B1 (https=)
TW (1) TWI869410B (https=)
WO (1) WO2020252014A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102833111B1 (ko) * 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106246A1 (en) * 1998-05-28 2005-05-19 Byrd Edward A. Controlled release arginine alpha-ketoglutarate
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1512403A1 (en) * 1999-12-03 2005-03-09 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
AU2002228955B2 (en) * 2000-12-20 2005-09-29 Alcon Inc. Solution for removing cataracts via liquefracture
US20060029668A1 (en) * 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) * 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
US11331287B2 (en) * 2013-06-06 2022-05-17 Balchem Corporation Iron supplement
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108721242B (zh) * 2015-06-03 2021-03-02 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106246A1 (en) * 1998-05-28 2005-05-19 Byrd Edward A. Controlled release arginine alpha-ketoglutarate
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOGAN J:, HYDROXYPROPYLMETHYLCELLULOSE SUSTAINED RELEASE TECHNOLOGY, 1 January 1989 (1989-01-01) *

Also Published As

Publication number Publication date
EP3980001B1 (en) 2025-08-27
BR112021024952A2 (pt) 2022-02-15
KR20220044478A (ko) 2022-04-08
TW202112362A (zh) 2021-04-01
JP2022537685A (ja) 2022-08-29
TWI869410B (zh) 2025-01-11
JP7751291B2 (ja) 2025-10-08
CN114126601A (zh) 2022-03-01
AU2020292278A1 (en) 2022-01-06
CA3142494A1 (en) 2020-12-17
AU2020292278B2 (en) 2026-02-12
CN114126601B (zh) 2025-07-15
IL288782A (en) 2022-02-01
WO2020252014A1 (en) 2020-12-17
EP3980001A4 (en) 2023-06-21
EP3980001A1 (en) 2022-04-13
US20220265586A1 (en) 2022-08-25
JP2025124683A (ja) 2025-08-26
ES3054304T3 (en) 2026-02-02
DK3980001T3 (da) 2025-12-01

Similar Documents

Publication Publication Date Title
HUE061482T2 (hu) Szintézismódszer
SG11202105907QA (en) Compositions for drg-specific reduction of transgene expression
GB201916960D0 (en) Compositions
DK3924442T3 (en) Compositions
IL289557A (en) Sustained release formulations of endoxifen
IL306029A (en) Preparations with improved bioavailability of medical treatments
IL289125A (en) the vehicles
GB201913701D0 (en) Composition of matter
GB201904612D0 (en) Reaction of glycoladehyde
IL288782B1 (en) Sustained-release alpha-ketoglutarate preparations
IL304159A (en) A preparation containing bl-8040
GB201908396D0 (en) Compositions
SG11202102204PA (en) Process of making calcium alpha-ketoglutarate
IL290324A (en) Preparations containing tropintide
GB202103774D0 (en) Detectiion of Ransomware
GB201919234D0 (en) Compositions
GB201903055D0 (en) Method of oligonucleaotide synthesis
IL291368A (en) Inhibits expression of methadherin
HK40071851A (en) Sustained-release compositions of alpha-ketoglutarate
GB201910665D0 (en) Novel form of compounds
IL309876A (en) Preparation of converted amidoximes
PL4040985T3 (pl) Granulacja topinamburu
GB201906917D0 (en) Novel compositions
GB201916122D0 (en) New compositions
GB201912411D0 (en) Crystalline forms of ivosidenib